Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504258 | 0.91 | ADRA1A (0.41) | ADRA2AADRA1AIDO1CHRNA7SIGMAR1 | |
| SCHEMBL78975 | 0.79 | ADRA2A (0.43) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL5521623 | 0.77 | ADRA2A (0.42) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL11380019 | 0.76 | GID4 (0.40) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL7498131 | 0.75 | PRCP (0.51) | MEN1KMT2AGID4 | |
| SCHEMBL17760557 | 0.74 | ADRA2A (0.45) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL8967058 | 0.73 | ADRA2A (0.47) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL22319970 | 0.72 | GID4 (0.61) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL4721678 | 0.72 | ALDH1A1 (0.30) | CYP2D6ALDH1A1 | |
| SCHEMBL4721538 | 0.72 | CYP1B1 (0.32) | CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261588-B1 | IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS | ORION CORP (FI) | 2004-10-20 | — | — | EP | claimed |
| US-6388090-B2 | IMIDAZOLE DERIVATIVES CONTAINING BICYCLIC AROMATIC OR AN HETEROCYCLIC RING FUSED WITH BENZENE EXHIBIT AFFINITY FOR ALPHA2 ADRENOCEPTORS SO TREATS THE DISEASE AFFECTED BY ALPHA2 ADRENOCEPTORS, E.G. NUROLOGICAL, PSYCHIATRIC OR COGNITION | ORION CORPORATION (FI) | 2002-05-14 | — | — | US | claimed |
| US-20010056109-A1 | Imidazole derivatives | ORION CORPORATION (FI) | 2001-12-27 | — | — | US | claimed |
| US-8017649-B2 | Flavonoid compounds and uses thereof | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2011-09-13 | — | — | US | disclosed |
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2009-05-21 | — | — | US | disclosed |
| EP-1261588-B1 | IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS | ORION CORP (FI) | 2004-10-20 | — | — | EP | disclosed |
| US-6388090-B2 | IMIDAZOLE DERIVATIVES CONTAINING BICYCLIC AROMATIC OR AN HETEROCYCLIC RING FUSED WITH BENZENE EXHIBIT AFFINITY FOR ALPHA2 ADRENOCEPTORS SO TREATS THE DISEASE AFFECTED BY ALPHA2 ADRENOCEPTORS, E.G. NUROLOGICAL, PSYCHIATRIC OR COGNITION | ORION CORPORATION (FI) | 2002-05-14 | — | — | US | disclosed |
| US-20010056109-A1 | Imidazole derivatives | ORION CORPORATION (FI) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056109-A1 | Imidazole derivatives | ADRB2, ADRB1, ADRA1D | ADRA2A 8/4885ADRA1A 4/4885CYP2D6 267/4885 |
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | CAT, NQO1, GPX4 | ADRA2A 2496/4885ADRA1A 2072/4885CYP2D6 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.